세계의 중추신경계 바이오마커 시장 규모 조사 및 예측, 유형별, 용도별, 최종 사용자별, 지역별 분석(2022-2029년)

Global Central Nervous System Biomarkers Market is valued approximately at USD 4.19 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 9.00% over the forecast period 2022-2029. A central nervous system (CNS) biomarker is a measurable substance or characteristic that provides information about the status or function of the central nervous system, which includes the brain and spinal cord. Biomarkers can include molecules such as proteins, metabolites, or genetic markers, as well as imaging or electrophysiological measurements. CNS biomarkers can be used for various purposes, such as diagnosing neurological disorders, monitoring disease progression, evaluating treatment efficacy, or predicting outcomes. The Central Nervous System Biomarkers market is expanding because of factors such as increasing incidences of neurological disorders and increasing research and development with successful clinical trials of biomarkers.

Growing prevelance of neurological disorders across the globe is fostering the market growth. According to report from Alzheimer Disease International Organization, in year 2020, globally there were around 55 million people suffering from dementia and this figure is expected to reach at 78 million in year 2030 and 139 million by year 2050. Additionally, there are more studies in the pipeline to create biomarkers for a variety of diseases, which is anticipated to accelerate the market expansion, For instance in year 2019, The University of Rochester and MC10 Inc. announced their partnership to explore new digital biomarkers for illnesses of the central nervous system. Along with these, increased development in genomics, proteomics, and imaging systems and burgeoning investments from the government and players is creating a lucrative market growth opportunity. However, high Cost of Central Nervous System Biomarkers may hamper the market growth.

The key regions considered for the Global Central Nervous System Biomarkers Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominates the market in terms of revenue, owing to the dominance of branded products and the region's increasing disease prevalence. Whereas Asia Pacific is expected to grow with a fastest CAGR during the forecast period, owing to factors such as rising prevelance of neurological disorders, an increase in the number of collaborations for clinical trial, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.

Major market players included in this report are:

• Acumen Pharmaceuticals Inc.
• Alseres Pharmaceuticals Inc.
• vacta Life Sciences Limited
• Biomeriux (Banyan Biomarkers Inc.)
• Bio-Rad Laboratories Inc.
• G-Biosciences
• Merck KGaA
• Thermo Fisher Scientific Inc.
• Eli Lilly and Company (Avid radiopharmaceuticals Inc.)
• Proteome Sciences PLC (Service)

Recent Developments in the Market:

• In October 2021, Diadem announced the release of clinical data demonstrating that its AlzoSure biomarker test may forecast the course of Alzheimer's disease years before symptoms manifest.
• In August 202, Johnson & Johnson Services, Inc. has partnered with Enigma Biomedical Group to research two novel neuroimaging biomarkers, JNJ-64413739 and JNJ-64511070, in an effort to better understand Alzheimer's disease and other dementias.

Global Central Nervous System Biomarkers Market Report Scope:

• Historical Data: 2019-2020-2021
• Base Year for Estimation: 2021
• Forecast period: 2022-2029
• Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered: Type, Application, End User, Region
• Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
• Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Type:

• Safety Biomarkers
• Efficacy Biomarkers
• Validation Biomarkers
• Others

By Application:

• Drug Discovery and Development
• Personalized Medicine
• Other Applications

By End User:

• Diagnostic Labs
• Clinics/Hospitals
• Research Centers

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• RoLA
• Rest of the World

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
  • 1.2.1. Central Nervous System Biomarkers Market, by region, 2019-2029 (USD Billion)
  • 1.2.2. Central Nervous System Biomarkers Market, by Type, 2019-2029 (USD Billion)
  • 1.2.3. Central Nervous System Biomarkers Market, by Application, 2019-2029 (USD Billion)
  • 1.2.4. Central Nervous System Biomarkers Market, by End User, 2019-2029 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Central Nervous System Biomarkers Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Scope of the Study
  • 2.2.2. Industry Evolution
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Central Nervous System Biomarkers Market Dynamics

• 3.1. Central Nervous System Biomarkers Market Impact Analysis (2019-2029)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Increasing incidence of neurological disorders
    • 3.1.1.2. Increasing Research and Development with Successful Clinical Trials of Biomarkers
  • 3.1.2. Market Challenges
    • 3.1.2.1. High Cost of Central Nervous System Biomarkers
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Increased development in genomics, proteomics, and imaging systems
    • 3.1.3.2. Burgeoning investments from the government and players

Chapter 4. Global Central Nervous System Biomarkers Market: Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economic
  • 4.3.3. Social
  • 4.3.4. Technological
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. Industry Experts Prospective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

• 5.1. Assessment of the overall impact of COVID-19 on the industry
• 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Central Nervous System Biomarkers Market, by Type

• 6.1. Market Snapshot
• 6.2. Global Central Nervous System Biomarkers Market by Type, Performance - Potential Analysis
• 6.3. Global Central Nervous System Biomarkers Market Estimates & Forecasts by Type 2019-2029 (USD Billion)
• 6.4. Central Nervous System Biomarkers Market, Sub Segment Analysis
  • 6.4.1. Safety Biomarkers
  • 6.4.2. Efficacy Biomarkers
  • 6.4.3. Validation Biomarkers
  • 6.4.4. Others

Chapter 7. Global Central Nervous System Biomarkers Market, by Application

• 7.1. Market Snapshot
• 7.2. Global Central Nervous System Biomarkers Market by Application, Performance - Potential Analysis
• 7.3. Global Central Nervous System Biomarkers Market Estimates & Forecasts by Application 2019-2029 (USD Billion)
• 7.4. Central Nervous System Biomarkers Market, Sub Segment Analysis
  • 7.4.1. Drug Discovery and Development
  • 7.4.2. Personalized Medicine
  • 7.4.3. Other Applications

Chapter 8. Global Central Nervous System Biomarkers Market, by End User

• 8.1. Market Snapshot
• 8.2. Global Central Nervous System Biomarkers Market by End User, Performance - Potential Analysis
• 8.3. Global Central Nervous System Biomarkers Market Estimates & Forecasts by End User 2019-2029 (USD Billion)
• 8.4. Central Nervous System Biomarkers Market, Sub Segment Analysis
  • 8.4.1. Diagnostic Labs
  • 8.4.2. Clinics/Hospitals
  • 8.4.3. Research Centers

Chapter 9. Global Central Nervous System Biomarkers Market, Regional Analysis

• 9.1. Central Nervous System Biomarkers Market, Regional Market Snapshot
• 9.2. North America Central Nervous System Biomarkers Market
  • 9.2.1. U.S. Central Nervous System Biomarkers Market
    • 9.2.1.1. Type breakdown estimates & forecasts, 2019-2029
    • 9.2.1.2. Application breakdown estimates & forecasts, 2019-2029
    • 9.2.1.3. End User breakdown estimates & forecasts, 2019-2029
  • 9.2.2. Canada Central Nervous System Biomarkers Market
• 9.3. Europe Central Nervous System Biomarkers Market Snapshot
  • 9.3.1. U.K. Central Nervous System Biomarkers Market
  • 9.3.2. Germany Central Nervous System Biomarkers Market
  • 9.3.3. France Central Nervous System Biomarkers Market
  • 9.3.4. Spain Central Nervous System Biomarkers Market
  • 9.3.5. Italy Central Nervous System Biomarkers Market
  • 9.3.6. Rest of Europe Central Nervous System Biomarkers Market
• 9.4. Asia-Pacific Central Nervous System Biomarkers Market Snapshot
  • 9.4.1. China Central Nervous System Biomarkers Market
  • 9.4.2. India Central Nervous System Biomarkers Market
  • 9.4.3. Japan Central Nervous System Biomarkers Market
  • 9.4.4. Australia Central Nervous System Biomarkers Market
  • 9.4.5. South Korea Central Nervous System Biomarkers Market
  • 9.4.6. Rest of Asia Pacific Central Nervous System Biomarkers Market
• 9.5. Latin America Central Nervous System Biomarkers Market Snapshot
  • 9.5.1. Brazil Central Nervous System Biomarkers Market
  • 9.5.2. Mexico Central Nervous System Biomarkers Market
  • 9.5.3. Rest of Latin America Central Nervous System Biomarkers Market
• 9.6. Rest of The World Central Nervous System Biomarkers Market

Chapter 10. Competitive Intelligence

• 10.1. Top Market Strategies
• 10.2. Company Profiles
  • 10.2.1. Acumen Pharmaceuticals Inc.
    • 10.2.1.1. Key Information
    • 10.2.1.2. Overview
    • 10.2.1.3. Financial (Subject to Data Availability)
    • 10.2.1.4. Product Summary
    • 10.2.1.5. Recent Developments
  • 10.2.2. Alseres Pharmaceuticals Inc.
  • 10.2.3. vacta Life Sciences Limited
  • 10.2.4. Biomeriux (Banyan Biomarkers Inc.)
  • 10.2.5. Bio-Rad Laboratories Inc.
  • 10.2.6. G-Biosciences
  • 10.2.7. Merck KGaA
  • 10.2.8. Thermo Fisher Scientific Inc.
  • 10.2.9. Eli Lilly and Company (Avid radiopharmaceuticals Inc.)
  • 10.2.10. Proteome Sciences PLC (Service)

Chapter 11. Research Process

• 11.1. Research Process
  • 11.1.1. Data Mining
  • 11.1.2. Analysis
  • 11.1.3. Market Estimation
  • 11.1.4. Validation
  • 11.1.5. Publishing
• 11.2. Research Attributes
• 11.3. Research Assumption